{"type":"trials","record":{"id":21786,"source_id":"clinicaltrials-gov","external_id":"NCT07328100","title":"Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","brief_summary":"Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.","overall_status":"Not Yet Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Shanghai 10th People's Hospital","enrollment":60,"countries":["China"],"start_date":"2026-01-16","completion_date":"2027-12-31","last_update_date":"2026-01-08","source_url":"https://clinicaltrials.gov/study/NCT07328100","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-24T01:17:10.338673+00:00","last_seen_at":"2026-09-25T06:10:49.917+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"40 Years to 70 Years","comparator":"Control Group","organization":"Shanghai 10th People's Hospital","interventions":["Coenzyme I for Injection","NaCl (placebo)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["The change in flow-mediated vasodilation(FMD) — Day 8/28","Changes in cf-PWV. — day 8/28","Changes in retinal arteriovenous ratio (AVR) and wall/lumen ratio (WLR) — day 8/28","Changes in the level of NAD+ — day 8/28","Changes in the metabolomics. — day 8/28","Changes in office blood pressure and 24-hour ambulatory blood pressure — day 8/28","The change in the urine albumin-to-creatinine ratio — day 8/28"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Vascular Aging","NAD","Coenzyme I for Injection","NaCl (placebo)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: vascular aging.","quality_checked_at":"2026-09-25T06:10:57.79658+00:00","duplicate_cluster_key":"id:nct07328100","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-01-16 to 2027-12-31","comparator":"Control Group","confidence":"structured-source","population":"ALL · 40 Years to 70 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:49.932Z","intervention":["Coenzyme I for Injection","NaCl (placebo)"],"participants":60,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The change in flow-mediated vasodilation(FMD) — Day 8/28","Changes in cf-PWV. — day 8/28","Changes in retinal arteriovenous ratio (AVR) and wall/lumen ratio (WLR) — day 8/28","Changes in the level of NAD+ — day 8/28","Changes in the metabolomics. — day 8/28","Changes in office blood pressure and 24-hour ambulatory blood pressure — day 8/28","The change in the urine albumin-to-creatinine ratio — day 8/28"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"cardiovascular-aging","is_published":true,"match_reasons":["Title contains controlled term: vascular aging.","Abstract contains controlled term: vascular aging, arterial stiffness.","Source terminology contains: vascular aging.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Cardiovascular ageing","slug":"cardiovascular-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/21786","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}